MML Investors Services LLC Purchases 19,113 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

MML Investors Services LLC increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 103.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,566 shares of the medical equipment provider's stock after buying an additional 19,113 shares during the quarter. MML Investors Services LLC's holdings in Zimmer Biomet were worth $4,055,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Dunhill Financial LLC grew its position in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet during the third quarter worth about $28,000. Bangor Savings Bank acquired a new position in Zimmer Biomet during the third quarter worth approximately $31,000. Family Firm Inc. bought a new stake in Zimmer Biomet in the second quarter valued at approximately $33,000. Finally, Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the 3rd quarter worth approximately $35,000. 88.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ZBH shares. Wells Fargo & Company raised their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an "equal weight" rating in a report on Thursday, October 31st. Oppenheimer lowered their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating on the stock in a report on Tuesday, October 15th. Royal Bank of Canada boosted their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the stock an "outperform" rating in a report on Monday, November 4th. Wolfe Research began coverage on Zimmer Biomet in a research note on Tuesday, September 10th. They set a "peer perform" rating on the stock. Finally, Evercore ISI reduced their price target on Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating for the company in a research note on Tuesday, October 1st. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $122.83.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock traded down $0.10 during trading on Friday, reaching $106.74. 1,195,338 shares of the company's stock were exchanged, compared to its average volume of 1,361,031. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The company has a market cap of $21.25 billion, a P/E ratio of 20.29, a PEG ratio of 1.96 and a beta of 1.02. The firm's 50-day moving average price is $107.69 and its 200 day moving average price is $108.75.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the previous year, the firm earned $1.65 earnings per share. The business's quarterly revenue was up 4.1% on a year-over-year basis. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.